Ixazomib-Based Maintenance Therapy Improves Prognosis of Patients with Multiple Myeloma: A Real-World Study

被引：0
|
作者：
Hong, Xiuli [1 ]
Chen, Jie [1 ]
Lu, Jingyuan [1 ]
Lu, Quanyi [1 ]
机构：
[1] Xiamen Univ, Zhongshan Hosp, Sch Med, Dept Hemotol, Xiamen, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-201297
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7014 / 7015
页数：2
相关论文
共 50 条
  • [21] Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma
    Soo Chin Ng
    Joon-Ho Moon
    Sung Soo Park
    Youngil Koh
    Ji Hyun Lee
    Hyeon-Seok Eom
    Ho-Jin Shin
    Sung Hoon Jung
    Young Rok Do
    Gilbert Wilfred
    Azlan Husin
    Hyo Jung Kim
    SFadilah Abdul Wahid
    Myung-Won Lee
    Hye-won Heo
    Kihyun Kim
    Suporn Chuncharunee
    International Journal of Hematology, 2025, 121 (5) : 670 - 683
  • [22] Real-World Outcomes of Ixazomib in the Treatment of Multiple Myeloma from a Single Center in China
    Sui, Weiwei
    An, Gang
    Deng, Shuhui
    Xu, Yan
    Hao, Mu
    Fu Mingwei
    Wang, Tingyu
    Yi, Shuhua
    Zhao, Yaozhong
    Zou, Dehui
    Li, Zengjun
    Qiu, Lugui
    BLOOD, 2019, 134
  • [23] Real World Use of Ixazomib With Lenalidomide and Dexamethasone for Patients With Relapsed Multiple Myeloma
    Lawson, Gabrielle
    Ziff, Monica
    De-Silva, Dunnya
    Cheesman, Simon
    Kyriakou, Charalampia
    Mehta, Atul
    Mahmood, Shameem
    Papanikolaou, Xenofon
    Rabin, Neil
    Sachchithanantham, Sajitha
    Sive, Jonathan
    Wechalekar, Ashutosh
    Yong, Kwee
    Popat, Rakesh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E264 - E264
  • [24] Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.
    Tandon, Nidhi
    Lacy, Martha
    Buadi, Francis
    Leung, Nelson
    Go, Ronald S.
    Dingli, David
    Kapoor, Prashant
    Gertz, Morie A.
    Lin, Yi
    Dispenzieri, Angela
    Drake, Matthew
    Hwa, Yi Lisa
    Fonder, Arnie
    Hobbs, Miriam
    Hayman, Suzanne R.
    Zeldenrust, Steven R.
    Lust, John Anthony
    Gonsalves, Wilson I.
    Rajkumar, S. Vincent
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] The Efficacy and Safety Profile of Ixazomib-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice: Real World Data from a Multi-Center Study in China
    Li, Jing
    Bao, Li
    Xia, Zhong-jun
    Ding, Kaiyang
    Li, Bingzong
    Chen, Bing
    Fu, Zhengzheng
    Wang, Sili
    Zhang, Wenhao
    Zhou, Xin
    Hua, Luoming
    Yang, Wei
    Jun, Luo
    Wang, Liang
    Xu, Tianhong
    Yang, Yang
    Wang, Weida
    Wu, Guolin
    Huang, Yun
    Liu, Peng
    BLOOD, 2019, 134
  • [26] Real-world Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone (IRd) in Asian Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Moon, Joon-Ho
    Ng, Soo Chin
    Park, Sung Soo
    Koh, Youngil
    Lee, Ji Hyun
    Eom, Hyeon-Seok
    Shin, Ho-Jin
    Lee, Je-Jung
    Do, Young Rok
    Wilfred, Gilbert
    Husin, Azlan
    Kim, Hyo Jung
    Wahid, S. Fadilah Abdul
    Lee, Myung-Won
    Heo, Hye-won
    Kim, Kihyun
    Chuncharunee, Suporn
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S263 - S264
  • [27] Therapeutic efficacy of ixazomib-based regimen in frail patients with newly diagnosed multiple myeloma based on the dynamic assessment of frailty
    Xue, Hua
    Xu, Mei Jian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S103 - S104
  • [28] Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study
    Cheng, Fu Cheng
    Jin, Song
    Zhuang, Junling
    Zhou, Xin
    Zhou, Fan
    Li, Yuhua
    Ding, Kaiyang
    Niu, Ting
    Chen, Wenming
    Fang, Baijun
    Chen, Li-Li
    Fu, Rong
    Zhang, Hao
    Fu, Jiaping
    Wang, Xiuju
    Liu, Sha
    Li, Lin
    Wu, Depei
    BLOOD, 2024, 144 : 6970 - 6971
  • [29] Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
    Huang, Shang-Yi
    Chen, Tsai-Yun
    Kuo, Ching-Yuan
    Chen, Yeu-Chin
    Lin, Sheng-Fung
    Chang, Ming-Chih
    Lv, Xinzhu
    Yang, Betty
    Chang, Cheng-Shyong
    ONCOLOGY REVIEWS, 2019, 13 (01) : 15 - 22
  • [30] Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
    Terpos, Evangelos
    Ramasamy, Karthik
    Maouche, Nadjoua
    Minarik, Jiri
    Ntanasis-Stathopoulos, Ioannis
    Katodritou, Eirini
    Jenner, Matthew W.
    Plonkova, Hana
    Gavriatopoulou, Maria
    Vallance, Grant D.
    Pika, Tomas
    Kotsopoulou, Maria
    Kothari, Jaimal
    Jelinek, Tomas
    Kastritis, Efstathios
    Aitchison, Robin
    Dimopoulos, Meletios A.
    Zomas, Athanasios
    Hajek, Roman
    ANNALS OF HEMATOLOGY, 2020, 99 (05) : 1049 - 1061
12345